Carbohydrate Antigen 125-guided Therapy in Heart Failure
Status:
Completed
Trial end date:
2015-05-01
Target enrollment:
Participant gender:
Summary
Preliminary data suggest a potential role for monitoring and up-titrate pharmacological
therapy of plasma levels of antigen carbohydrate 125 (CA125) following and admission for
acute heart failure (AHF).
This study will evaluate the effect of a CA125-guided management strategy versus standard
therapy on the composite endpoint of 1-year all-cause mortality or readmission for AHF in
patients recently discharged for AHF.
Phase:
Phase 4
Details
Lead Sponsor:
Fundación para la Investigación del Hospital Clínico de Valencia
Collaborator:
Ministerio de Sanidad, Servicios Sociales e Igualdad